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Applications, and Recent 
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Abstract
Pharmacogenomics is defined as the study of genes and how an individual 
response is affected due to drugs. Pharmacogenomics is an emerging new branch 
with combination of both pharmacology (the branch of science that deals with 
study of drugs) as well as genomics (the branch of science that deals with study of 
genes) for development of effective doses and safe medications tailored according 
an individual patient genetic makeup. Human Genome Project is one of the crucial 
projects in which researchers are developing and learning relation in genes and its 
effect on the body’s response to medications. Difference in genetic makeup provides 
difference in effectiveness of medication and in future to predict effectiveness 
of medication for an individual and to study existence of adverse drug reactions. 
Besides advancement in the field of science and technology till date pharmacoge-
nomics hangs in infancy. There is limited use of pharmacogenomics, but still, novel 
approaches are under clinical trials. In near future, pharmacogenomics will enable 
development of tailor-made therapeutics for treating widespread health problems 
like neurodegenerative, cardiovascular disorders, HIV, cancer, asthma, etc.
Keywords: pharmacogenomics, genomics, proteomics, personalized medicines, 
tailored drugs
1. Pharmacogenomics: Overview
Due to variability existence among individuals against drug therapy response, it 
is a challenging task to predict the degree of effectiveness of a medication to a par-
ticular patient. As we know various clinical factors which are known to affect drug 
response, for example body size, age, sex, hepatic and renal function, and associated 
drug use (Table 1). Along with these clinical factors, some pharmacological factors 
also play a major role which includes differences in metabolism, drug distribution 
and drug directed proteins [2, 3]. Recently, major causes of interindividual differ-
ences are shown by variations in genes encoding cytochrome P450 (CYP) and other 
metabolizing enzymes in plasma concentrations of some drugs [4, 5].
Pharmacogenetics and pharmacogenomics can be used interchangeably. 
Though, Pharmacogenomics refers to the whole range of genes that are related to 
the determination of drug efficacy and safety whereas pharmacogenetics means 
monogenetic variants which alter the drug response [6, 7]. Pharmacogenomics 
is defined as study of genes and how they affect an individual response to the 
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administered drugs. Pharmacogenomics is emerging new branch with combination 
of both pharmacology (branch of science which deals with study of drugs) as well 
as genomics (the branch of science which deals with study of genes) for develop-
ment of effective doses and safe medications tailored according an individual 
patient genetic makeup (Figure 1) [8, 9].
Basically, the concept for pharmacogenetics was left unknown for more than 
50 years. This study underlined to the molecular mechanisms in account for their 
variation in responses to drug due to inherited characters and in drug development 
process. Pharmacogenomics applications can be employed in the improvement 
of discovery of new entities and its development with two possible ways: target 
the new drug targets or development of new entity to overcome drug resistance, 
and another way is to optimize the pharmacokinetics and metabolism of drug for 
reduction of the drug level variations [10]. In fact, personalized drug therapy or 
individualized drug therapy is not an easy task. It needs many folds as there may be 
a lack of information regarding drug action, genomic elements of important disease 
pathogenesis, especially for complex diseases. Also, large scale clinical studies are 
sometimes becoming a big challenge for the researchers [11]. The correlation of 
pharmacogenomics and cancer would expand the specific anticancer drugs with 
better chemotherapeutic outcomes [12–15]. There are prominent examples with 
recent clinical and pharmaceutical restrains where the molecular based mechanisms 
are involved in various drug responses were observed among the patients and 
diagnosed with the similar diseases [16, 17]. Moreover, various polymorphisms 
existence at genetic levels in genes found to have association with alteration in 
responses of drug and rate of ADRs in humans (Table 2) [18].
Finally, pharmacogenomics-based development of drug and its regulation will 
open the doors for new as well as targeted drug development for promoting safe, 
effective, and cost-effective drug therapy for individual. The theoretical origin for 
pharmacogenomics is outlined by Sir Archibald Garrod’s in book entitled as “1939 
Inborn Factors of Disease” [19].
Pharmacogenetics is the study of how an individual person’s genes respond 
to a drug. This branch is associated with genomics is genetic level studies with 
functional studies and pharmacology (includes pharmacokinetics and pharmaco-
dynamics). All these branches together aid in the development of safe, and effective 
medications along with doses which are probably tailored to an individual persona 
genetic makeup [20–24]. Pharmacogenetics is indicated as major clinically proven 
Factors Effects
a. Genetic factors
Drug-metabolizing enzymes Drug metabolism (pharmacokinetics)
Therapeutic targets Drug efficacy (pharmacodynamics)
Targets of ADRs Drug toxicity
Drug transporters Drug disposition
b. Environmental factors
Environmental chemicals, alcohol drinking, 
combined drugs effect, and dietary substances
Drug efficacy, toxicity, and pharmacokinetics
c. Physiological factors
Age, sex, pregnancy, exercise, disease state, 
starvation
Drug efficacy, toxicity, and pharmacokinetics
Table 1. 
Genome-wide association studies in pharmacogenomics [1].
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application in terms of advancement in human genomic science. This potentiates a 
revolution in drug therapy. As a result, diseases which range from depression to viral 
infection and from childhood leukemia to hypertension are treated or controlled 
for enhancing the quality of life of patient. Most medicines at present are available 
as “one medication fits all” but they sometimes were not capable to work same to 
everyone. So, it is difficult to envisage who will have benefit result and who will have 
negative side effects. Also, the knowledge which scientist have acquired due to exten-
sive work on Human Genome Project and are learning about inherited variations 
of genes and there effect on body’s response to medications. Conditions in which 
responses of an individual to certain drugs include Stevens-Johnson syndrome or 
epidermal toxic necrolysis, clopidogrel resistance, malignant hyperthermia, warfarin 
sensitivity and its resistance and thiopurine S-methyltransferase deficiency [25].
Figure 1. 
Development of pharmacogenomics and pharmacogenetics.
Polymorphic gene Drug Effect
CYP2C9 Phenytoin Toxicity
Warfarin Bleeding risk
Glipizide Hypoglycaemia
TPMT Anticancer drugs like 6-thiopurine, 
6-Mercaptopurine, azathioprine
Toxicity
Human leukocyte antigens (HLA) Abacavir Related to 
hypersensitivity
N-acetyltransferase (NATs) Sulphonamides, hydralazine, 
Isoniazid
Toxicity, 
hypersensitivity
UDP-glucuronosyltransferase 1A1 
(UGT1A1)
Irinotecan Toxicity
CYP2D6 Codeine Toxicity
Fluoxetine Toxicity
MDRI Antiepileptic drugs Drug response
Table 2. 
Genes with altered drug response.
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2. Application
Many common diseases having high morbidity as well as mortality rates have 
now known with well-established genetic components. The degree of role of 
genetics has been predicted for diseases like obesity and diabetes according to their 
sibling analysis [26, 27]. In the same way, some rare gene mutations can provide 
a vision into the more complex biological processes [28]. For instance, when the 
subject possesses extreme levels of HDL in their blood, one can easily demonstrated 
the influence of CETP (cholesteryl ester transfer protein) on patients HDL levels 
[29–31]. In another case, a person having deactivating mutations due to the Janus 
kinase 3 (JAK 3) gene shows severe combination of immune-deficient syndrome, as 
sometimes inhibition of JAK3 was expected to affect the human immune suppres-
sion [32, 33]. Hence, this led to a new investigation on drugs having CETP inhibition 
and JAK3 inhibition with the help of pharmacogenetics [34]. Also, with the advent 
of pharmacogenomics, the path of relationships between disease state and human 
genes has now established which led to the suitable selection of therapeutic targets.
Nowadays, many academic institutions and Pharmaceutical companies are 
moving toward the investigation on the relationship between disease phenotypes 
and genetic variations to better categorize diseases [35, 36]. Although the collection 
of medical phenotypes having linkages with samples of DNA provides a promi-
nent opportunity for examine the genetic variation which are present in patients. 
Investigation of genetic variation can be done by collection of DNA of particular 
patient. This is characterized in a study where DNA from a person involves in trails 
of lipid lowering demonstrated a swift connection between phenotypic novel 
lipase gene family and for HDL levels. As per literature reports, above mentioned 
studies are based on a sound hypothesis which is linked to candidate’s biological 
gene selection. Now it is easy to cross-examine the genome selection which is solely 
depends on phenotypic criteria [10, 37]. These stages have now substituted around 
300,000 SNPs across the genome, by exploiting only few haplotype-defining SNPs. 
Perlegen sciences have developed newly genotyping technologies which has with a 
capability of genotyping mass hundreds or thousands of markers with the help of 
high-density based oligonucleotide arrays linked with restriction enzyme-based 
genomic reduction. However, as these technologies advances, still exact number of 
haplotype-defining SNPs is uncertain. Some findings are recently reported relation 
to assess polymorphisms across selected gene regions recommends that, it is neces-
sary to reach an r2 of >0.8% in order to detect more than 80% of all haplotypes. Due 
to HapMap project progression with defined LD patterns linkage, scientist work-
ing on genes will thorough assess to the degree of LD in a represented regions or 
selected regions. This will enable to explore more around selection of SNP regard-
less design of study [38, 39]. As genome approach does not depend upon selection 
of candidate genes, so understanding on complex diseases such as psychiatric or 
cardiovascular diseases will become more efficient. Some researchers believed that 
the new horizons on LD coverage about insights of human genome and SNP density 
will show the perception of a substantial genomic portion areas and its relation with 
interest of phenotype [40, 41]. To assess the Perlegen Sciences chip-based array-
based platform and to justify the haplotype tagging approach for the identification 
of genetic associations, 7283 SNPs connecting 17.1 mega bases (Mb) of DNA were 
genotyped for detecting linkages with HDL levels. Further, SNPs were connected 
with 50 CETP haploblock gene were found out as the most valuable association 
in dataset. The companies like Perlegen and project like Hap Map project recently 
declared their purpose to provide it SNPs markers into public provinces to further 
advent to basis for such kind of experiments which help in the scientific community 
[42, 43].
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Pharmacogenetics significantly expands the therapy outcomes and drug uses. 
Medications may prescribe in low dose under strict monitoring to patients which 
shows genetically predisposed to their adverse events. This would probably helpful 
for drugs having narrow therapeutic index such as warfarin may be started gradually 
in patients having VKORC1 genotype linked with improved warfarin sensitivity. 
With the help of pharmacogenetics, it is now possible to reduce the number of 
subjects to conduct any experiment and chances of error may be eliminated for 
many diseases [44, 45].
On the contrary, clinicians may be able to minimize possible adverse effects 
with the aid of genetic information for matching suitable drug to suitable patient 
at an appropriate dose. For instances, traditional approach to the management of 
hypertension involves the trial of numerous anti-hypertensive drugs till the desired 
blood pressure achieved with adequate drug tolerability. In this case, few initial 
drugs/agents fail to produce lower blood pressure or shown intolerable adverse 
effects. This way of selection of drugs took long time which ultimately suffered by 
patients. On the contrary, Pharmacogenetics, based on the patients’ DNA, offers 
the greatest response with the best tolerability of the drug. Based on genetic regula-
tor of cellular functions, pharmacogenetics may be able to produce new drugs 
with less adverse effects. For example, chromosome translocation and its derived 
enzymes are responsible for causing life-threatening chronic myeloid leukemia 
(CML) which led to accelerate FDA approval of inhibitor of translocation-created 
enzyme Imatinib [46]. In the end, this core subject improves the quality and cut-
down the total costs of healthcare by minimizing the number of adverse reaction 
and reduce treatment failures gives rise to the discovery of new genetic targets for 
disease management [47–49].
3. Case studies
3.1 Thiopurine therapy and TPMT (thiopurine methyltransferase) testing
Thiopurine are the categories of drugs that are used to conquer the normal 
activity of the body’s immune system. In short, these are called antimetabolites 
chiefly used as an antiproliferative as well as immunosuppressants such as mer-
captopurine and azathioprine. 6-mercaptopurine daily administered for 3–4 years 
for treating childhood leukemia, while azathioprine which is a prodrug of 6-mer-
captopurine prescribed for treating inflammatory bowel disease (also known as 
Crohn’s disease) [50]. TPMT methylates thiopurine compounds. S-adenosyl-L-
methionine acts as methyl donor and converts it into S-adenosyl-L-homocysteine 
[51, 52]. So, TPMT metabolizes various thiopurine based drugs with mechanism 
of S-adenosyl-L-methionine while S-methyl acting as donor, while S-adenosyl-L-
homocysteine acting as a derivative. Genetic polymorphism which affects basi-
cally enzymatic activity has association with variations in toxicity and sensitivity 
within individuals due to such drugs. Nearby 1/300 individual is lacking for 
this enzyme. TPMT has not recognized to have any phenotype in the absence of 
encounter drug. TPMT is now enlists by FDA as a pharmacogenomic biomarker 
for various adverse drug reactions related to cisplatin such as cisplatin-induced 
ototoxicity in teenagers [47, 53–55].
Patients having identical alleles at equivalent chromosomal loci accumulate 
unnecessary thioguanine nucleotides levels (up to 10-fold higher related with 
wild types) and treatment with standard dosages of drug and leading to a hema-
topoietic toxicity (pancytopenia and myelosuppression) which is life-threatening 
condition [56, 57].
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In more concise way, patients having heterozygous gene variations are also at 
high risk in terms of toxicity and dosage reductions is prior in these cases up to their 
tolerate therapy. According to pharmacoeconomic studies, the determination of the 
TPMT genotype is cost-effective and it must be checked prior to the start of ther-
apy. According to a review of the literature, it was found that TPMT testing with 
clinical performances for myelosuppression was estimated with specificity of 89%, 
sensitivity of 32%, 9% PPV and NPV of 97% (Table 3). The low estimated value 
represents low incidence of severity in myelosuppression especially in those patients 
who are carrier of not less than one defective allele. Researchers have estimated the 
net cost for avoidance of serious events of myelosuppression. Out of 1000 patients 
receiving azathioprine, only 3.2% (equivalent to 32 cases) have founded with severe 
leukopenia and TPMT screening avoided as third of those trials [50, 58].
Iorio and co-workers have analyzed drug responses on various human cancer 
cell lines. The mapping was done for around 11K tumors obtained from different 
29 different human tissues as per Cancer of Genome Atlas (TCGA) enlisted from 
1000 cancer cell lines as per Genomics of Drug Sensitivity in Cancer resource. 
In another event, TCGA patient gene expression was studied for drug response. 
In this, more than 140 gene drug interactions were studied with specific somatic 
biomarkers [59–61].
3.2 Abacavir therapy and HLA testing
Abacavir which is HIV-1 nucleoside with reverse transcriptase inhibition is 
employed for management of HIV/AIDS. It is well tolerated but sometimes shows 
common to more severe side-effects which include lactic acidosis, hypersensitivity 
[62]. In some studies, it was observed that a genetic testing/marker can help in pre-
dicting whether a HIV-infected patient is at high risk of abacavir induced severe 
hypersensitivity reactions (approx. 5% of patients) [63, 64]. This hypersensitivity 
reaction accompanies with lethal gastrointestinal symptoms, rashes, and fever. 
This reaction is life threatening, particularly if drug is restarted and discontinued. 
One study has shown about an occurrence of human leukocyte antigen (HLA)
B05701 is main cause of hypersensitivity [45, 65]. Based on the Australian cohort, 
patients were 114 times more hypersensitivity due to HLA-B5701 allele reaction, 
whereas in an industry-sponsored study revealed that patients with the HLA-B5701 
allele was associated with 24 times more likely to experience of hypersensitivity 
reaction [45]. Thus, one way to solve this issue is genetic testing which integrates 
pharmacogenetics into the clinical practice. The distribution of HLA-B5701 allele 
can be detected in many worldwide populations (Table 4).
3.3 Statin therapy and polymorphic angiotensin-converting enzyme
Statins (HMGCoA) reductase inhibitors most often used in management of 
hypercholesterolemia condition accompanying with elevation in risk to coronary 
heart disease [66, 67]. Due to increased number of cases of hypercholesterolemia 
along with volume of statins related prescriptions in US, it creates a significant 
interest in optimization of costs related to these therapies [31]. Recent investiga-
tions have told that polymorphism in I/D angiotensin converting enzyme (ACE) 
has correlation with risk of heart related syndromes in men when treated with 
statins [68–70]. Next 2 years of statin medication, in which males who are having 
DD genotype (equivalent to 27% of patients) shown to have no effect on the risk 
of coronary heart disease (with relative risk factor of 1.34), in comparison to 
males with ID (equivalent to 21% of patients) present a marked decreased in risk 
of coronary cardiovascular disease (with relative risk rate of 0.87), II genotype 
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(equivalent to 22% of patients) having relative risk of 0.23, thus concluding 
that patients bearing DD genotype did not take advantages from statin treat-
ment. Also, testing of I/D genotype might results in cost effective as few patients 
presents the I/I or I/D genotype [70].
3.4 Muscle relaxant succinylcholine and antitubercular drug, INH
These two conventional illustrations of pharmacogenetics involve the genetic 
variation along with enzymatic metabolism (enzymatic hydrolysis and acetylation). 
Both act as a monogenic trait and involved PK variations because of inheritance dif-
ferences [71, 72]. It was observed that some patients with succinylcholine treatment 
experienced a serious and lethal adverse event i.e. prolonged muscle paralysis which 
is due to inherited “atypical” butyryl cholinesterase enzyme (BCHE). Later, it was 
established that BCHE allele which encodes the most usual atypical form of enzyme 
comprised with a nonsynonymous coding i.e. single nucleotide polymorphism 
(nSNP), G209 > A, results in Asp70 > Gly change in encoded amino acid which 
altered active sites of enzyme [73, 74]. But atypical BCHE has less ability to cata-
lyze the succinylcholine hydrolysis and could resist to inhibition due to dibucaine 
compound [37, 75].
Tuberculosis is the most problematic disease of both developing as well as 
under-developed nations. The conformity to patients with tuberculosis is due to 
common lethal adverse reactions and supposed to have important aspect providing 
high prevalence [76, 77]. Many investigations showed that the polymorphisms of 
N-acetyl transferase 2 (NAT-2), CYP2E1 as well as glutathione S transferase (GST-
1) would be able to influence concentration of liver toxic isoniazid metabolites in 
plasma. Some polymorphic genes contribute in the INH induced hepatotoxicity by 
Population group HLA-B5701 carrier frequency range (%)
Asian 00–6.5
Southwest Asian 4–19.5
Middle Eastern 0.5–6.2
African 0.0–3.5
European 1.5–10.5
Mexican 0.0–4.2
South American 1.2–3.2
Table 4. 
Allele frequency of HLA-B5701 allele in various population groups.
Clinical performances (%)
Percent responders 40.0
Sensitivity 75.0
Specificity 66.7
Frequency mutation 50.0
Positive predictive value (PPV) 60.0
Negative predictive value (PPV) 80.0
Table 3. 
Clinical performances of the test.
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altering the anti-oxidant enzyme expression, these gene polymorphisms include 
glucuronosyltransferase (UGT), basic region of leucine zipper factor family (CNC) 
homolo (BACH), human leukocyte antigen (HLA), nitric oxide synthase (NOS) and 
Maf basic leucine zipper protein (MAFK). Till date the above mentioned studies 
encounter with many limitations [77–79].
3.5 Warfarin
Warfarin is a medication that is commonly used as an anticoagulant which 
means blood thinner. It aids in treating blood clots such as pulmonary embolism 
and deep vein thrombosis, and to prevent heart diseases associated with clotting. It 
has very narrow therapeutic index [80, 81]. However, warfarin therapy may result 
in complicated adverse reactions including both coagulation and hemorrhage. The 
racemic mixture of warfarin, S-form is 3–5 times more potent in comparison to 
R-form of an anticoagulant, and easily gets metabolized due to genetically polymor-
phic CYP450 isoform i.e. CYP2C9 [82]. CYP2C9 exists in two common polymorphic 
form, Arg144 > Cys (CYP2C9*2) as well as Ile358 > Leu (CYP2C9*3) modifications 
in coded sequence of amino acid, with nearly 12 and 5%, respectively. These forms 
vary between 8 and 10% in Caucasians, with minor occurrence in subject from 
Southeast Asia. A report in 1999, which confirms patients with one or two common 
CYP2C9 variant alleles, requires a “low” warfarin dose. These subjects had a risen 
risk of hemorrhage during warfarin therapy. In 2004, the gene encoded targeting 
VKORC1 (vitamin K epoxide reductase complex 1) was cloned. In a study, it was 
found that patients with VKORC1 type of haplotypes requires low dose, the average 
warfarin maintenance dose was nearly half for subjects with haplotypes having 
high dose maintenance. In this study, the grouping of both VKORC1 haplotyping as 
well as genotyping for CYP2C9 described around 25% of dose variance in warfarin. 
Other studies reported similar results in 2005. The Pharmacogenetics Knowledge 
Base (PharmGKB), in which data base is reinforced by the National Institutes of 
Health (NIH) along with part of the NIH Pharmacogenetics Research Network 
(PGRN), originated an association for consolidation of warfarin pharmacogenetic 
data throughout the world [83, 84]. In this evaluation of variation in genetic drug 
target as well as drug metabolism if and only if when VKORC1 and CYP2C9 hap-
lotypes were determined. The figure demonstrates a schematic illustration of both 
pharmacokinetic (CYP2C9-dependent) as well as pharmacodynamic (VKORC1-
dependent) pharmacogenomic aspects that effects final dose of warfarin (Figure 
2).
It is important to know that by identifying the individual genetic properties, we 
can improve the dosing of warfarin. In general, VKORC1 haplotypes have three-fold 
greater effect on an individual’s warfarin dose than CYP2C9. Both can play a vital 
role in the potential for estimating the therapeutic warfarin dose. In August 2007, 
FDA approved a change in labeling of warfarin package stating, “lower starting 
doses should be considered for patients with some genetic alterations in VKORC1 
and CYP2C9 enzymes” [80].
4. Outlook
These cases prove that patient care could be improved effectively by pharmaco-
genetic based approaches. Although, the allelic occurrences of the gene alterations 
must be visibly defined in the subjects studied must be well established. Out of 
above-mentioned cases, no one is absolute, so it is better to perform the sensitiv-
ity analyses as well as to regulate the robustness of conclusion with variation in 
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probabilities [85, 86]. Move onward, it is utmost important for maintaining the 
possible cost-effectiveness of few recently published pharmacogenetic associated 
reports, for instance, vitamin K epoxide reductase gene variants envisage the war-
farin response [87–89]. Lastly, it will be significant to collect pharmacoeconomic 
and pharmacogenetic statistics together during industry-funded clinical trials for 
bringing cost effective theragnostic in a sensible manner [90, 91].
5. Conclusion
Individualized therapeutics or tailor-made therapy is one of the major goals 
of pharmacogenomics. In relation to inheritance other factors also contribute to 
individual therapeutics due to variation in response to administration of drug. 
Recently many developments in the field of pharmacology and genomics have 
made possible for physicians to achieve individualization of therapeutics. These 
recent developments create possibility of thorough basis of particular drug for 
particular patient with motive of tailor-made therapy. Futuristic development in 
field of pharmacogenomics has paved the way to new emerging fields of pharma-
coproteomic, pharmacotranscriptomics, and pharmacometabolomic. These new 
branches of science make it possible to achieve the concept of treat each patient 
as unique, complex, fascinating individual. At the end doubts about achieving 
individualized therapeutics with the help of this integrated system is still a dream 
in 21st century era.
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